Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Functional Assessment Using QFR for the Revascularization of Non-Culprit Lesions in AMI Patients

Nowadays, evidence from studies and meta-analyses has demonstrated the benefits of complete revascularization compared to culprit-vessel-only revascularization in patients with acute myocardial infarction (AMI). The identification and treatment of non-culprit lesions can be guided by conventional angiography, intracoronary imaging, or coronary physiology; the optimal modality, however, is still unclear.

IAM

Quantitative flow ratio (QFR) is a type of functional assessment derived from angiography that doesn’t require a coronary guidewire. Various studies have assessed this tool, including FAVOR III (Functional Assessment by Virtual Online Reconstruction), which demonstrated that QFR-based revascularization reduces the incidence of major cardiovascular events. However, the role of QFR in treating non-culprit lesions in AMI patients remains uncertain.

The objective of this multicenter, randomized study was to assess the predictive capability of QFR for adverse events and to evaluate the non-inferiority of QFR-guided management for treating non-culprit lesions.

The primary endpoint (PEP) was a composite of cardiac death, target vessel myocardial infarction (TVMI), and ischemia-driven target vessel revascularization (id-TVR). The secondary endpoint (SEP) included the individual components of the PEP.

The FIRE (Functional Assessment in Elderly MI Patients With Multivessel Disease) study randomized 1145 AMI patients into two groups: culprit-vessel-only revascularization (n=725) and complete physiology-guided revascularization (n=720). The mean age of the participants was 81 years, and most subjects were men. The most frequent clinical presentation was non-ST segment elevation MI (about 60%), followed by ST segment elevation MI.

Read also: EuroPCR 2024 | Self-Expanding Valves (ACURATE Neo2) vs. Balloon-Expandable Valves (Sapien 3 Ultra): 1-Year Follow-up Results.

The most frequently affected vessel was the left anterior descending artery, followed by the right coronary artery, the circumflex artery, and the left main coronary artery. QFR was measured in 903 non-culprit vessels of 685 patients in the culprit-only group. In total, 366 (40.5%) of the non-culprit vessels showed a QFR value ≤0.80, with a significantly higher incidence of the PEP (22.1% vs. 7.1%; P <0.001).

A QFR ≤0.80 emerged as an independent predictor of the PEP (hazard ratio [HR]: 2.79; 95% confidence interval [CI]: 1.64-4.75). In the complete revascularization group, QFR was used in 320 (35.2%) non-culprit vessels to guide revascularization. There were no significant differences in the PEP when comparing the treatments of non-culprit vessels guided by QFR-based functional assessment (HR: 0.57; 95% CI: 0.28-1.15).

Conclusion

This study demonstrated that QFR can be safely used to identify non-culprit lesions requiring revascularization in AMI patients with multivessel disease.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: QFR for the Revascularization of Nonculprit Vessels in MI Patients Insights From the FIRE Trial.

Reference: Andrea Erriquez, MD et al J Am Coll Cardiol Intv 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...